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Abstract
TLR signaling is essential to innate immunity against microbial invaders and must be tightly 
controlled. We have previously shown that TLR9 undergoes proteolytic cleavage processing by 
lysosomal proteases to generate two distinct fragments. The C-terminal cleavage product plays a 
critical role in activating TLR9 signaling; however, the precise role of the N-terminal fragment, 
which remains in lysosomes, in the TLR9 response is still unclear. In this article, we report that 
the N-terminal cleavage product negatively regulates TLR9 signaling. Notably, the N-terminal 
fragment promotes the aspartic protease-mediated degradation of the C-terminal fragment in 
endolysosomes. Furthermore, the N-terminal TLR9 fragment physically interacts with the C-
terminal product, thereby inhibiting the formation of homodimers of the C-terminal fragment; this 
suggests that the monomeric C-terminal product is more susceptible to attack by aspartic 
proteases. Together, these results suggest that the N-terminal TLR9 proteolytic cleavage product is 
a negative self-regulator that prevents excessive TLR9 signaling activity.
Toll-like receptors are critical sensors for pathogen-associated molecular patterns, and they 
play key roles in provoking innate immune responses and enhancing adaptive immunity 
against microbial infection (1, 2). In resting myeloid cells, the predominant intracellular 
localization of TLR3, TLR7, TLR8, and TLR9 in the endoplasmic reticulum (ER) changes 
to an endolysosomal compartment, wherein they mediate the recognition of viral and 
bacterial nucleic acids (3–6). TLR ligation triggers recruitment of signaling adaptor 
molecules that leads to NF-κB activation and induces the expression of genes encoding 
immune and proinflammatory molecules (7, 8). Although TLR signaling is essential for the 
host’s immune response to pathogens, excessive activation of TLR signaling contributes to 
Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved.
Address correspondence and reprint requests to Prof. Boyoun Park, Department of Systems Biology, College of Life Science and 
Biotechnology, Yonsei University, Seoul 120-749, South Korea. bypark@yonsei.ac.kr.
1S.L. and D.K. contributed equally to this work.
Disclosures
The authors have no financial conflicts of interest.
The online version of this article contains supplemental material.
NIH Public Access
Author Manuscript
J Immunol. Author manuscript; available in PMC 2015 April 01.
Published in final edited form as:
J Immunol. 2014 October 1; 193(7): 3726–3735. doi:10.4049/jimmunol.1400210.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
autoimmune and chronic inflammatory diseases (9). TLR signaling must thus be tightly 
controlled to maintain a proper immune balance.
Recent studies have reported that TLR9 undergoes proteolytic processing by endolysosomal 
proteases to generate the C-terminal cleavage fragment, which functions as an active 
receptor that is required for the binding of CpG-DNA and initiation of signal transduction 
(10–12), and the N-terminal half of the TLR9 ectodomain is required for DNA sensing (13). 
However, the precise functional role of the N-terminal fragment of TLR9, which remains 
with the C-terminal product in the endolysosome after proteolytic cleavage, is still not 
clearly understood. In this article, we report that the N-terminal cleavage product of TLR9 
accelerates the dissociation of C-terminal fragment dimerization through physical interaction 
and promotes aspartic protease-mediated degradation of the C-terminal fragment, thus 
blocking TLR9 signal transduction. Our results collectively show an autoregulatory negative 
feedback mechanism of TLR9 activation by an N-terminal cleavage product in C-terminal–
mediated signal transduction, suggesting that TLR9 is a self-regulatory protein. This is 
necessary to induce TLR tolerance capable of preventing fatal inflammatory conditions, 
which are associated with autoimmune diseases.
Materials and Methods
DNA constructs
All mouse TLR9-related constructs were fused at the C terminus to Myc or GFP. Wild-type 
TLR9-Myc, recombinant C-terminal TLR9 fragment (Cterm), and Unc93b-hemagglutinin 
(HA) have been described previously (10, 14). The recombinant N-terminal TLR9 fragment 
(Nterm-TM-GFP) was generated by overlap extension PCR with the primers 5′-
GCTAGATCTGCCACCATGGTTCTCCGTCGAAGGACTCTG-3′ (XbaI-TLR9; forward), 
5′-
ACAGCCAAGAGTGAAAGGCCAAAGCACCTGTCCATGAAGTTCTTAGAAGCAGG-
3′ (TM-470; reverse), 5′-
CCTGCTTCTAAGAACTTCATGGACAGGTGCTTTGGCCTTTCACTCTTGGCTGT-3′ 
(470-TM; forward), and 5′-ATGCGTCGACCCGAGATGGTGCAGTATAGGCACCAC-3′ 
(SalI-TM-TLR9; reverse), and was finally fused at the C terminus with GFP (pEGFP-N1). 
TM-GFP encoding the TLR9 TM was fused at the N terminus with the H2-Kb signal 
sequence (MVPCTLLLLLAAALAPTQTRA). Nterm-Δ441-470-TM-GFP encoding the N-
terminal TLR9 fragment and TM, but not the cleavage site, was generated by overlap 
extension PCR with the primers 5′-
GTCAGAAGCCACCCCTGAAGAGTGCTTTGGCCTTTCACTCTTGGCTG-3′ (440-TM; 
forward) and 5′-
CAGCCAAGAGTGAAAGGCCAAAGCACTCTTCAGGGGTGGCTTCTGAC-3′ 
(TM-440; reverse). Two different TLR9 ectodomain constructs tagged at the C terminus 
with Myc (Nterm-440-Myc [1–440] and Nterm-470-Myc [1–470]) were generated by PCR 
with the primers 5′-ATTAGATCTGCCACCATGGTTCTCCGTCGAAGGACTC-3′ 
(forward), 5′-
CGTAGAATTCTTACAAGTCCTCTTCAGAAATGAGCTTTTGCTCCTCTTCAGGGGT
GGCTTCTGACAG-3′ (Nterm-440-Myc [1–440]; reverse), and 5′-
Lee et al. Page 2
J Immunol. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
CGTAGAATTCTTACAAGTCCTCTTCAGAAATGAGCTTTTGCTCCCTGTCCATGAA
GTTCTTAGAAGCAGG-3′ (Nterm-470-Myc [1–470]; reverse). All constructs were cloned 
into the retroviral pMSCV (puro) or pLHCX (hygro) vector (Clontech, Mountain View, CA) 
and were verified by sequencing.
Reagents
1826-CpG DNA and 1826-Biotin-CpG DNA (5′-Bio-TsCsCsAsTsg-
sAsCsgsTsTsCsCsTsgsAsCsgsTsT-3′) were purchased from TIB Molbiol (Berlin, 
Germany). PNGase F and endoglycosidase H (Endo H) were purchased from New England 
Biolabs (Ipswich, MA). The monoclonal Myc Ab (catalog no. 2276) and GFP Ab (catalog 
no. ab290) were obtained from Cell Signaling Technology (Danvers, MA) and Abcam 
(Cambridge, U.K.), respectively. Streptavidin agarose beads and LPS (Escherichia coli 026: 
B6) were purchased from Pierce (Rockford, IL) and Sigma-Aldrich (St. Louis, MO). 
Proteasome inhibitor, MG132, and lysosomal proteases inhibitor, chloroquine, were 
purchased from Sigma-Aldrich. Aspartic protease inhibitor, pepstatin A (catalog no. 
516481), was purchased from Calbiochem (Darmstadt, Germany).
Mice and cell lines
All animals were maintained under specific pathogen-free conditions according to 
guidelines set by the committee for animal care at Yonsei University. Immortalized wild-
type and TLR9-deficient bone marrow–derived macrophages (BMDMs) were obtained from 
BEI Resources. Murine RAW 264.7 macrophages (ATCC TIB-71), human embryonic 
kidney (HEK) 293T cells (ATCC CRL-11268), and immortalized bone marrow macrophage 
cell lines were cultured in DME supplemented with 10% heat-inactivated FBS and 
penicillin/streptomycin. Cells were grown at 37°C in humidified air with 5% CO2.
Retroviral transduction
HEK 293T cells were transfected with plasmids encoding VSV-G and Gag-Pol, as well as 
pMSCV-TLR9-Myc, pLHCX-Cterm-Myc, pMSCV-Cterm-GFP, pMSCV-Nterm-TM-GFP, 
pMSCV-Nterm-Δ441-470-TM-GFP, or pMSCV-TM-GFP. Forty-eight hours after 
transfection, media containing viral particles were collected, filtered through a 0.45-μm 
membrane, and incubated with RAW macrophages, immortalized macrophages, or bone 
marrow–derived dendritic cells (BMDCs) for 24 h. Cells were selected with puromycin or 
hygromycin for 48 h or 4 d.
Preparation of BMDMs
BMDCs were prepared as described previously (15). In brief, BMDM cells were generated 
from wild-type C57BL/6 mice (Orient Bio, Gyeonggi-do, South Korea), in medium 
containing 25 ng/ml M-CSF (Biolegend, San Diego, CA). Femurs and tibiae were collected 
from 4-wk-old mice. After removing bone-adjacent muscles, we extracted marrow cells by 
flushing with a 25-gauge needle. Bone marrow cells were then resuspended in DMEM (10% 
FBS and 1% antibiotics) with M-CSF (5 ng/ml). Fresh medium was replenished on days 2 
and 4. BMDMs were generated after 6–8 d of culture.
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Pulse-chase analysis, immunoprecipitation, and Endo F/H assay
Cells were “starved” for 1 h in medium without methionine and cysteine, then were labeled 
with [35S]methionine/cysteine and chased for the indicated times. Cells were lysed with 1% 
Nonidet P-40 (NP-40) in PBS supplemented with protease inhibitors for 1 h at 4°C. After 
pre-clearing of lysates with protein G-Sepharose (Sigma-Aldrich), primary Abs and then 
protein G-Sepharose were added to the supernatants and incubated at 4°C. The protein G-
Sepharose beads were washed five times with 0.1% NP-40/PBS. Proteins were eluted from 
the beads by boiling in 1% SDS. Digestion with PNGase F or Endo H (New England 
Biolabs) was performed at 37°C for 3 h. For coimmunoprecipitation experiments, cells were 
lysed in 1% digitonin (Calbiochem) in buffer containing 25 mM HEPES, 100 mM NaCl, 10 
mM CaCl2, and 5 mM MgCl2 (pH 7.6) supplemented with protease inhibitors. Buffers 
containing 0.1% digitonin were used for all subsequent steps. Bound proteins were eluted by 
boiling in SDS sample buffer or 1% SDS. Proteins were separated by SDS-PAGE, 
transferred onto a nitrocellulose membrane, blocked with 5% skim milk in PBS with 0.1% 
Tween 20 (Sigma-Aldrich) for 2 h, and probed with the appropriate Abs for 4 h at room 
temperature. Membranes were washed three times with PBS with 0.1% Tween 20 and 
incubated with HRP-conjugated streptavidin for 1 h. The immunoblots were visualized with 
ECL detection reagent (Pierce).
ELISA
Cells were treated with 1 μM CpG-DNA or 80 ng/ml LPS for 12 h. The media were 
collected and analyzed by ELISA using hamster anti-mouse/rat IL-6 (BD Biosciences, San 
Jose, CA) as a capture Ab and biotin-labeled rabbit anti-mouse as a secondary Ab (BD 
Biosciences).
Intracellular staining for IL-6
BMDCs were cultured for 5 d with GM-CSF and were incubated with normal DMEM. Cells 
were then stimulated with agonists for 6 h in the presence of 10 μg/ml brefeldin A. The cells 
were fixed with 4% formaldehyde for 10 min at room temperature and permeabilized with 
0.5% saponin in FACS buffer (PBS with 2% BSA and 0.05% sodium azide) for 10 min. 
Cells were stained with PE-conjugated anti–IL-6 (Biolegend, San Diego, CA) for 30 min. 
Fluorescence intensity was measured on a flow cytometer (BD Biosciences).
Immunofluorescence assay
For immunofluorescent staining, cells were fixed in 3.7% formaldehyde and permeabilized 
with 0.1% Triton X-100 before incubation with TAMRA-CpG-DNA (Life Technologies, 
Carlsbad, CA) or LysoTracker (Life Technologies). Cells were imaged using a fluorescence 
microscope.
Luciferase assay
HEK293T cells in 12-well plate were transfected with 150 ng NF-κB firefly luciferase, 10 
ng Renilla luciferase, 100 ng Unc93B1, and 150 ng full-length TLR9 or C-term of TLR9 in 
combination with 100 ng TM-GFP, Nterm-TM-GFP, Nterm 440-Myc, or Nterm 470-Myc. 
After 24 h, cells were stimulated with 1 μM CpG-DNA for 12 h; luciferase assays were 
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performed using Dual-Luciferase Reporter Assay System (Promega, Madison, WI) and 
Victor X5 (Perkin Elmer, Waltham, MA). Firefly luciferase activity was normalized to 
Renilla luciferase activity.
Ethics statement
All animal experiments were performed in accordance with the Korean Food and Drug 
Administration guidelines. Protocols were reviewed and approved by the Institutional 
Animal Care and Use Committee of Yonsei Laboratory Animal Research Center. All mice 
were maintained in the specific pathogen-free facility of the Yonsei Laboratory Animal 
Research Center.
Results
Generation of lysosomal-targeted N-terminal TLR9 recombinant fragments
In the endolysosomal compartment, TLR9 is proteolytically cleaved into a C-terminal 
fragment, which is capable of immune signaling (10, 11), and an N-terminal cleavage 
fragment, the functional role of which is still unclear. Onji et al. (13) showed that the N-
terminal half of the TLR9 ectodomain is required for DNA sensing; however, the effect of 
the TLR9 ectodomain construct lacking the transmembrane region might be different from 
the original properties of the N-terminal fragment of TLR9, which remains with the C-
terminal product in the endolysosome after proteolytic cleavage. To address the precise role 
of the N-terminal cleavage product in TLR9 signaling, we first needed to express only the 
TLR9 N-terminal region in the endolysosomal compartment. We generated the TLR9 
chimeras TLR9 Nterm-TM-GFP and TM-GFP (Fig. 1A). TLR9 Nterm-TM-GFP contains 
the TLR9 N-terminal fragment (residues 1–440), the cleavage site comprising the region 
corresponding to aa 441–470, and the TM that is critical for binding Unc93B1, which is 
responsible for facilitating transport to endolysosomes from the ER (14, 16). The use of the 
GFP tag at the C terminus allowed us to determine whether the chimera was cleaved at the 
cleavage site in the endolysosome, as the chimera proteins can be detected using an anti-
GFP Ab. TM-GFP encodes the TLR9 transmembrane region and the GFP tag at the C 
terminus, and is used as a negative control. We next established RAW macrophage 
derivatives that stably expressed either Nterm-TM-GFP or TM-GFP. We examined whether 
Nterm-TM-GFP is capable of interacting with Unc93B1. We found that Nterm-TM-GFP 
interacted with Unc93B1 (Fig. 1B). To further evaluate the ability of the chimeric proteins 
to relocate to the lysosome, we used LysoTracker and examined their colocalization after 
exposing cells to CpG-DNA. Although the relocation ability of these chimeras was not as 
high as wild-type TLR9, ~40% of chimeric proteins were able to translocate to the lysosome 
where they colocalized with CpG-DNA (Fig. 1C, 1D). Furthermore, based on detection of a 
band corresponding to TM-GFP, we concluded that Nterm-TM-GFP is proteolytically 
cleaved in lysosomes. These results suggest that the N-terminal cleavage fragment is indeed 
overexpressed in lysosomes (Fig. 1E).
We next examined the rates of TM-GFP or Nterm-TM-GFP biosynthesis and maturation by 
performing pulse-chase experiments and analyzing Endo H or Endo F digestion. We 
metabolically labeled RAW macrophages expressing wild-type TLR9-GFP, TM-GFP, or 
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Nterm-TM-GFP, chased for the indicated times, and recovered the proteins from lysates by 
immunoprecipitating with the anti-GFP Ab. Immunoprecipitates were digested with Endo H 
and Endo F. As shown in previous studies in BMDMs or RAW macrophages (10, 11, 17), 
wild-type TLR9 trafficked through the Golgi compartment, whereas full-length, Endo H–
resistant TLR9-GFP was barely detectable (Fig. 1F, upper panels). Although both chimeras 
were less stable than wild-type TLR9, the biosynthesis and maturation rates of Nterm-TM-
GFP and TM-GFP occurred with similar kinetics as wild-type TLR9 (Fig. 1F, bottom 
panels). Because the TM-GFP chimera does not have the extracellular domain containing 
multiple glycosylation sites, it was not cleaved by Endo H. We did not observe differences 
in kinetics or stability between TM-GFP and Nterm-TM-GFP. In addition, the kinetics of 
both chimeric proteins was not affected by the presence or absence of endogenous TLR9 
(Fig. 1F, bottom panels). We examined that trafficking of wild-type TLR9 was not affected 
by Nterm-TM-GFP or TM-GFP (Fig. 1G). Because Nterm-TM-GFP and TM-GFP do not 
have the C-terminal active region that is required for subsequent TLR9 signal transduction 
(10–12), TLR9−/− immortalized macrophages that expressed the chimeric constructs were 
unable to activate TLR9 signaling after treatment with CpG-DNA (Fig. 1H).
The N-terminal proteolytic cleavage product of TLR9 negatively regulates its signaling
We next assessed the specific functional effects of N-terminal cleavage fragments on TLR9 
stability and activation. We exposed RAW macrophages that stably expressed either TLR9 
Nterm-TM-GFP or TM-GFP to TLR4 (LPS) and TLR9 (CpG-DNA) agonists and measured 
IL-6 production. We found that overexpression of the N-terminal TLR9 cleavage product in 
endolysosomes inhibited IL-6 production by macrophages stimulated with CpG-DNA, but 
did not influence IL-6 release after LPS exposure (Fig. 2A). We also found that induction of 
TNF-α production by CpG-DNA was impaired upon TLR9-Nterm-TM-GFP overexpression 
in macrophages (Fig. 2B). Similarly, CpG-DNA–stimulated, immortalized macrophages that 
stably expressed Nterm-TM-GFP showed reduced IL-6 production. In contrast, CpG-DNA 
stimulation of immortalized macrophages expressing TM-GFP did not affect IL-6 synthesis 
(Fig. 2C). To confirm these findings, we used an NF-κB–luciferase reporter gene to examine 
whether the N-terminal fragment inhibits TLR9 signaling activation. Indeed, cells 
transfected with the N-terminal cleavage product inhibited TLR9 signaling (Fig. 2D). We 
thus conclude that the N-terminal TLR9 proteolytic cleavage product that is normally 
generated along with the C-terminal fragment by lysosomal proteases is an important 
negative regulator of TLR9 signaling.
The N-terminal TLR9 cleavage product targets a C-terminal active receptor for degradation 
in the endolysosome
To establish how the N-terminal fragment negatively controls TLR9 responses, we 
investigated whether the N-terminal fragment affects the interaction of full-length TLR9 
with Unc93B1. However, we observed no differences in this interaction between TM-GFP– 
and Nterm-TM-GFP–expressing cells (Fig. 3A). We next determined whether the N-
terminal TLR9 product influences proteolytic cleavage processing and generation of a C-
terminal fragment. In RAW macrophages expressing both full-length TLR9 tagged at the C 
terminus with Myc (TLR9-Myc) and Nterm-TM-GFP, we observed a significant reduction 
in C-terminal TLR9 cleavage products, but not in full-length TLR9. Unlike Nterm-TM-
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GFP–expressing macrophages, the introduction of TM-GFP did not affect the C-terminal 
fragment (Fig. 3B). Next, we sought to determine whether the reduced yield of C-terminal 
fragments was due to decreased stability of the C-terminal products. We generated RAW 
macrophages that stably expressed the recombinant C-terminal TLR9 fragment tagged at the 
C terminus with Myc (TLR9-Cterm-Myc), and transduced them with a retrovirus encoding 
Nterm-TM-GFP or TM-GFP. We found that the stability of the C-terminal fragment was 
reduced in Nterm-TM-GFP–expressing cells (Fig. 3C).
To test whether the N-terminal region that includes a TM affects the stability of the C-
terminal product, we generated an additional construct, Nterm-Δ441-470-TM-GFP, which 
contains the N-terminal TLR9 fragment and TM, but not the cleavage site. Unlike Nterm-
TM-GFP, cells transfected with Nterm-Δ441-470-TM-GFP did not degrade the C-terminal 
fragment (Fig. 3D). Moreover, cells transfected with Nterm-Δ441-470-TM-GFP did not 
efficiently inhibit the CpG-DNA–driven TLR9 response, suggesting that the endolysosomal 
cleavage process that generates the soluble N-terminal fragment is important for inhibition 
of TLR9 signaling (Fig. 3E). To confirm these results, we performed pulse-chase 
experiments. We found the N-terminal TLR9 fragment degraded the C-terminal fragment 
(Fig. 3F). Thus, we conclude that the N-terminal TLR9 fragment generated after proteolytic 
cleavage in the lysosome facilitates C-terminal fragment degradation.
Aspartic protease is necessary for degradation of the C-terminal TLR9 fragment by N-
terminal product
To investigate whether the degradation of the C-terminal fragment by the N-terminal TLR9 
cleavage product was dependent on either proteasomal or lysosomal proteases, we 
monitored the protein levels of a recombinant C-terminal fragment in N-terminal fragment-
expressing RAW macrophages in the presence of MG132 or chloroquine, an inhibitor of 
proteasome or lysosomal proteases. We found that the degradation of the C-terminal 
fragment by the N-terminal product was considerably inhibited by RAW macrophages 
treated with chloroquine but was unaffected by exposure to MG132 (Fig. 4A, lanes 3, 5, 6). 
In addition, to explore whether cathepsin activity was essential for TLR9 activation and is 
also involved in degradation of the C-terminal fragment in the N-terminal–mediated 
negative regulation, we exposed the RAW macrophages to z-FA-fmk, a cysteine protease 
inhibitor, or to pepstatin A, an inhibitor of aspartic proteases. Notably, z-FA-fmk had no 
effect on the degradation of the C-terminal fragment by the N-terminal TLR9 cleavage 
product, but the degradation was affected by pepstatin A (Fig. 4B, lanes 3–5). We concluded 
that the degradation of C-terminal product by the N-terminal TLR9 fragment is induced by 
aspartic proteases in the lysosome. In contrast, cathepsin shows no signs of such 
degradation, unlike generation of the functional C-terminal proteolytic cleavage product.
The N-terminal cleavage product blocks TLR9 C-terminal fragment dimerization by 
physically interacting with the C-terminal fragment
Full-length TLR9 forms homodimers in the absence of CpG-DNA, suggesting that TLR9 
dimers induce a conformational change capable of ligand binding and bringing the TIR 
domains in close proximity to recruit adaptor proteins to initiate signal transduction (18). In 
addition, Li et al. (19) reported that the cleaved C-terminal fragment usually forms a 
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monomer in solution, and that CpG-DNA enhances dimerization. To explore why the C-
terminal product is vulnerable to aspartic proteases in macrophages expressing the N-
terminal fragment, we analyzed the effect of the N-terminal TLR9 fragment on C-terminal 
cleavage product dimerization. We first examined whether recombinant C-terminal products 
form homodimers in RAW macrophages. We used RAW cells that stably coexpressed 
recombinant C-terminal TLR9 fragments tagged with either Myc (TLR9 Cterm-Myc) or 
GFP and exposed them to CpG-DNA. We immunoprecipitated TLR9 Cterm-Myc using the 
anti-Myc Ab and examined dimerization by immunoblotting with the anti-GFP Ab. We 
found that cleaved C-terminal TLR9 products formed homodimers even in the absence of 
CpG-DNA, and that homodimer formation was increased by CpG-DNA (Fig. 5A, lanes 7, 
8). We next investigated whether the N-terminal TLR9 product disrupts homodimerization 
of the C-terminal fragment. We used RAW macrophages that expressed Myc- or GFP-
tagged C-terminal TLR9 products with either Nterm-TM-GFP or TM-GFP and exposed 
them to an aspartic protease inhibitor to detect the C-terminal fragment, which is degraded 
by N-terminal product expression (Fig. 4). In the anti-Myc immunoprecipitates, we 
immunoblotted with the anti-GFP Ab and detected that the C-terminal product strongly 
interacted with the N-terminal fragment (Fig. 5B, lane 3). We also found that C-terminal 
product dimer formation was significantly reduced by N-terminal TLR9 product expression, 
suggesting that disruption of C-terminal product dimerization by the N-terminal fragment 
sensitizes the C-terminal functional receptor to aspartic protease degradation in the lysosome 
(Fig. 5B, lanes 2, 4).
We next analyzed the interaction between CpG-DNA and the C-terminal TLR9 fragment in 
the presence and absence of the N-terminal product. As expected, given the degradation of 
the C-terminal TLR9 fragment by aspartic proteases in the lysates of cells expressing the N-
terminal cleavage product, the association between the C-terminal TLR9 product and biotin-
CpG in Nterm-TM-GFP–expressing macrophages was much weaker than that in TM-GFP–
expressing cells (Fig. 5C, upper panel).
Because a previous study suggested that the N-terminal region of the TLR9 ectodomain 
participates in ligand binding (20), we examined whether the N-terminal product directly 
binds CpG-DNA (Fig. 5C, bottom). We found that the N-terminal fragment binds CpG-
DNA, implying that it could compete with the C-terminal fragment for DNA binding in the 
lysosome. To determine whether this is the case, we examined the influence of the N-
terminal product on the binding affinity of the C-terminal product for CpG-DNA in the 
presence of chloroquine because the lysosomal inhibitor blocks the ability of the N-terminal 
product to degrade the C-terminal fragment. Unlike control conditions, we did not observe a 
decreased interaction of biotin-CpG-DNA with the C-terminal product in Nterm-TM-GFP–
expressing macrophages treated with chloroquine (Fig. 5D). Therefore, we conclude that 
although the N-terminal product can bind CpG-DNA, it does not directly compete for CpG-
DNA binding. Rather, the N-terminal product selectively degrades the C-terminal product, 
thereby leading to reduced CpG-DNA binding.
To confirm the negative self-regulatory effect of the N-terminal product on TLR9 signaling 
in primary cells, we purified BMDCs and transduced them with a retrovirus encoding the N-
terminal fragment. After exposing these cells to LPS or CpG-DNA, we measured cytokine 
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production. BMDCs expressing Nterm-TM-GFP inhibited responsiveness to CpG-DNA 
stimulation, as indicated by IL-6 production. In contrast, IL-6 production was not affected 
by the CpG-DNA stimulation of BMDCs expressing TM-GFP (Fig. 5E). In addition, 
introduction of the N-terminal TLR9 product into TLR9−/− immortalized macrophages 
expressing wild-type TLR9 inhibited the CpG DNA-driven production of IL-6. In contrast, 
IL-6 production elicited by the LPS stimulation of BMDCs or TLR9−/− immortalized cells 
expressing Nterm-TM-GFP was not affected (Fig. 5F). We also observed that the N-terminal 
fragment inhibited signaling responses by the C-terminal cleavage fragment of TLR9 when 
stimulated with CpG-DNA, as monitored by an NF-κB–luciferase reporter gene (Fig. 5G). 
Although Onji et al. (13) have reported that the expression of the N-terminal ectodomain of 
TLR9 is involved in the full activation of TLR9 signaling, we failed to observe the full 
activation of TLR9 by a combination of the N-terminal and C-terminal fragments (Fig. 5G). 
Two different TLR9 ectodomain constructs tagged at the C terminus with Myc (Nterm-440-
Myc [1–440] and Nterm-470-Myc [1–470]) were seen to block the signaling activation of 
the C-terminal TLR9 cleavage product, as with the inhibition of the lysosomal N-terminal 
fragment. These results collectively established that the N-terminal TLR9 cleavage product 
inhibits the homodimerization of the C-terminal fragment through competitive inhibition by 
physical interaction, and thus facilitates the aspartic protease-dependent degradation of 
monomeric C-terminal active receptor. We therefore conclude that the N-terminal TLR9 
cleavage product is a negative self-regulator targeting the C-terminal functional receptor, a 
role that is crucial for the homeostasis of the TLR9 response.
The N-terminal portion of TLR9 has distinct functions in the ER or lysosome and a 
prolonged half-life compared with the C-terminal product
The recombinant C-terminal cleavage fragment activates NF-κB signaling and CpG-DNA–
driven TNF-α production; however, as shown previously, the levels of the activation appear 
lower than those observed with full-length TLR9 (10, 19). Thus, we hypothesized that the 
N-terminal portion of TLR9 has distinct functions in the ER and lysosome. We first 
examined whether the N-terminal portion in the ER helps full-length TLR9 translocate 
efficiently to the lysosome (Fig. 6A). Indeed, full-length TLR9 was more efficiently 
trafficked to the lysosome compared with the recombinant C-terminal product, suggesting 
the N-terminal portion supports effective full-length protein relocation from the ER to the 
lysosome. To further test the possibility that the N-terminal portion provides strong affinity 
for Unc93B1, we examined the binding affinity of full-length TLR9 or the recombinant 
TLR9 C-terminal product with Unc93B1. The binding affinity of the C-terminal product for 
Unc93B1 was very slightly reduced when compared with full-length TLR9, but we did not 
observe a significant difference in their binding affinity (Fig. 6B). This result suggests that 
the N-terminal region of the TLR9 ectodomain is capable of binding unknown adaptor 
proteins in the ER, which supports full-length TLR9 relocation to the lysosome.
To evaluate the stability profile of a cohort of newly synthesized full-length TLR9 or its N-
terminal or C-terminal fragments over time, we pulse-labeled TLR9-Myc–expressing 
macrophages with [35S]methionine/cysteine for 30 min and chased for the indicated times 
(Fig. 6C). Because the C-terminal fragment physically interacts with the N-terminal product, 
we evaluated the kinetics and stability of full-length TLR9 and its N- or C-terminal 
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fragments at each time point by immunoprecipitating with the anti-Myc Ab. As reported 
previously (10, 11, 21), we observed that TLR9 is proteolytically processed in a time-
dependent manner via a multistep process, and its processing was blocked upon treatment 
with z-FA-FMK, a cathepsin inhibitor (Fig. 6C). Interestingly, the stability of the C-terminal 
fragment was reduced by ~60 and 25% after 6 and 9 h, respectively, whereas the majority of 
the N-terminal fragments were highly stable throughout the chase period. These results 
suggest that the N-terminal fragment is more stable over time than the C-terminal fragment 
in endolysosomes. This results in a switch in the negative feedback mechanism of TLR9 
signaling by C-terminal product degradation.
Discussion
TLR signaling stimulates expression of inflammatory cytokines and antimicrobial proteins. 
However, prolonged or uncontrolled TLR activation leads to the development of septic 
shock and inflammatory diseases (22, 23). Therefore, signal-specific regulators responsible 
for repressing proinflammatory cytokines or blocking signal transduction pathways must 
negatively control TLR activation after the elimination of microbial populations. Proteolytic 
cleavage events are crucial for producing functional TLR9 receptors that bind CpG-DNA 
and initiate NF-κB activation (10–12). However, the role of the N-terminal TLR9 cleavage 
product generated after lysosomal protease–mediated cleavage was not elucidated in TLR9 
signaling. We have now demonstrated that the N-terminal TLR9 cleavage product facilitates 
dimer dissociation of C-terminal cleavage products through physical interactions between 
N- and C-terminal fragments, thereby allowing the C-terminal TLR9 product to be more 
susceptible to aspartic protease-mediated degradation in the endolysosomal compartment. 
The broad specificity inhibitor pepstatin A most effectively blocked this degradation and, 
accordingly, inhibited C-terminal product degradation in cells expressing the N-terminal 
TLR9 fragment. CpG-DNA binding with TLR9 induces dimer formation to allow TIR 
domains to recruit adaptor proteins (18, 19). Our data show that blocking C-terminal product 
dimers via physical interaction with the N-terminal fragment promotes aspartic protease-
mediated degradation of the C-terminal fragment, indicating that C-terminal product 
homodimer formation is necessary to prevent proteolytic degradation in the endolysosomal 
condition.
Various mutations within the N-terminal region of TLR9 cause its inactivation, and the N-
terminal half of the TLR9 ectodomain acts as a DNA sensor (19, 20), implying that the N-
terminal region might be required for full activation. In addition, although the C-terminal 
cleavage fragment activates cytokine production elicited by CpG-DNA or NF-κB signaling, 
the levels of TNF-α production or NF-κB activation seem to be lower than those seen with 
full-length TLR9 (10, 19). Our results showed that in the ER, the N-terminal portion of the 
TLR9 ectodomain supports effective relocation of full-length TLR9 to endolysosomes. Once 
trafficked to the lysosome, the N-terminal cleavage product generated by lysosomal 
proteases plays a key role in negative regulation of the TLR9 response in late stages of the 
immune response. It remains possible that the N-terminal region may contribute to 
enhancement of full-length TLR9 maturation in the ER or proteolytic cleavage processing in 
lysosomes and that the N-terminal product plays different roles in the TLR9 response to 
infection in a time-dependent manner.
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Soluble TLR2 (sTLR2), sTLR4, and sTLR9 can modulate their responses, thereby reducing 
inflammation and infection (24–27). Chockalingam et al. (25) previously showed that N-
terminally tagged sTLR9 is generated by proteolysis and observed in the lysosome. It is also 
detectable by Western blot analyses in HEK293T cells. However, as reported previously 
(11), we failed to detect N-terminal HA-tagged sTLR9 in RAW macrophages (Supplemental 
Fig. 1). Secondary-structure prediction programs show another small extended loop in TLR9 
(10) situated between LRR1 and LRR2 that could be another lysosomal protease cleavage 
site(s). It may be hard to detect N-terminally tagged fragments derived from N-terminally 
tagged full-length TLR9 because of their small size. Recent study has shown that the crystal 
structure of the C-terminal product of mouse TLR9 exhibits similarities to the structures of 
other nucleic acid–binding TLRs, particularly TLR8 C-terminal domain (28). However, 
more detailed structural analyses of TLR9 are necessary to understand the proteolytic 
cleavage events of TLR9.
In conclusion, our data demonstrate that remnant N-terminal cleavage products of TLR9 
generated by lysosomal proteases have a critical role as negative self-regulators of TLR9 
activation induced by C-terminal active receptors. In this manner, they maintain appropriate 
cytokine and chemokine production involved in TLR homeostasis.
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FIGURE 1. 
Generation of lysosomal-targeted TLR9 N-terminal cleavage fragments. (A) Schematic 
showing generation of lysosomal-targeted TLR9 N-terminal chimeric constructs. Nterm-
TM-GFP contains the N-terminal TLR9 proteolytic cleavage product, the cleavage sites 
(residues 441–470), TM, and GFP at the C terminus; TM-GFP encodes only the TLR9 TM 
and GFP. (B) RAW cells expressing TLR9 Nterm-TM-GFP in the presence or absence of 
Unc93B1-HA were lysed with 1% digitonin lysis buffer. Unc93B1 proteins were 
immunoprecipitated with the anti-HA Ab. Immunoprecipitated samples were resolved by 
SDS-PAGE and analyzed using anti-GFP Western blot analyses. (C) RAW cells expressing 
TM-GFP or TLR9 Nterm-TM-GFP were stimulated with 1 μM CpG-DNA for 1 h and 
washed. Cells were treated with LysoTracker and imaged using immunofluorescence assay. 
Scale bars, 5 μm. (D) RAW macrophages stably expressing TLR9 Nterm-TM-GFP were 
stimulated with 1 μM TAMRA-labeled CpG-DNA for 30 min, washed, and imaged after an 
additional 3-h incubation. Arrowheads indicate colocalization between Nterm-TM-GFP with 
CpG-B-TAMRA. Scale bars, 5 μm. (E) Lysates from RAW macrophages stably expressing 
Nterm-TM-GFP were analyzed by Western blot analyses using anti-GFP or anti–β-actin Ab. 
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(F, upper panels) Wild-type TLR9-GFP–expressing macrophages were labeled with 
[35S]methionine/cysteine and chased for 5 h. Cell lysates were immunoprecipitated with the 
anti-Myc Ab, and immunoprecipitates were treated with Endo H or Endo F. (F, bottom 
panels) B6 or TLR9−/− immortalized macrophages stably expressing TM-GFP or Nterm-
TM-GFP were labeled with [35S]methionine/cysteine for 30 min and chased for the 
indicated times. Each chimeric protein was recovered using the anti-GFP Ab, followed by 
treatment with Endo H. (G) Nterm-TM-GFP does not affect trafficking of wild-type TLR9. 
RAW cells expressing empty vector, TM-GFP, or TLR9 Nterm-TM-GFP in the presence of 
full-length TLR9-Myc were lysed with 1% NP-40 lysis buffer. Lysates were 
immunoprecipitated with the anti-Myc or anti-GFP Ab. Immunoprecipitated proteins were 
resolved by SDS-PAGE and analyzed using anti-Myc or anti-GFP Western blot analyses. 
(H) The N-terminal TLR9 product does not activate TLR9 signaling. ELISA showing IL-6 
production by TLR9−/− immortalized macrophages stably expressing empty vector, TM-
GFP, Nterm-TM-GFP, or wild-type TLR9, stimulated for 12 h with CpG-DNA (1 μM). Data 
are representative of at least three independent experiments (average ± SD).
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FIGURE 2. 
The N-terminal TLR9 proteolytic cleavage product negatively regulates its signaling. (A) 
The influence of the N-terminal cleavage product on TLR9 signaling. IL-6 production was 
measured in RAW macrophages expressing TM-GFP or Nterm-TM-GFP after stimulation 
for 12 h with LPS (80 ng/ml), CpG-DNA (1 μM), or titration with the indicated 
concentrations of CpG-DNA. IL-6 production was measured by ELISA. (B) TNF-α 
production by macrophages stably expressing TM-GFP or Nterm-TM-GFP exposed for 12 h 
to CpG-DNA (1 μM). (C) IL-6 production by wild-type immortalized macrophages stably 
expressing TM-GFP or Nterm-TM-GFP after stimulation with LPS (80 ng/ml) or CpG-DNA 
(1 μM) for 12 h. (D) NF-κB luciferase reporter assays of HEK293T cells expressing full-
length TLR9 in the presence of the indicated expression plasmids were performed 12 h after 
stimulation with 1 μM CpG-DNA. *p < 0.05 (Student t test). Data are representative of at 
least three independent experiments (average ± SD).
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FIGURE 3. 
The N-terminal cleavage product degrades C-terminal active receptor. (A) RAW 
macrophages expressing either TM-GFP or TLR9 Nterm-TM-GFP were lysed with 1% 
digitonin lysis buffer. TLR9-Myc proteins were immunoprecipitated with the anti-Myc Ab. 
Immunoprecipitated samples were resolved by SDS-PAGE and analyzed by Western blot 
analyses using the Unc93B1, Myc, or β-actin Ab. (B) TLR9 stability in RAW macrophages 
expressing either TM-GFP or Nterm-TM-GFP was monitored by immunoblotting with anti-
Myc, anti-GFP, or anti–β-actin. Full-length TLR9 was tagged at the C terminus with Myc. 
TLR9-FL, full-length TLR9; TLR9 Cterm, C-terminal fragment of TLR9. (C) Immunoblot 
analyses of the recombinant Myc-tagged C-terminal TLR9 fragment (residues 471–1032) in 
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RAW macrophages expressing either TM-GFP or Nterm-TM-GFP. Lysates were 
immunoblotted with anti-Myc, anti-GFP, or anti–β-actin. (D) Immunoblot analyses of the 
recombinant Myc-tagged C-terminal TLR9 fragment in RAW macrophages expressing 
either TM-GFP or Nterm-Δ441-470-TM-GFP. (E) IL-6 production by macrophages stably 
expressing TM-GFP or Nterm-Δ441-470-TM-GFP exposed for 12 h to CpG-DNA (1 μM). 
*p < 0.01 (Student t test). (F) Wild-type TLR9-Myc–expressing macrophages stably 
expressing either TM-GFP or Nterm-TM-GFP were labeled with [35S]methionine/cysteine 
for 1 h and chased for the indicated times. Cell lysates were immunoprecipitated with the 
anti-Myc Ab, and immunoprecipitates were treated with Endo H. Data are representative of 
three independent experiments. Data are representative of at least three independent 
experiments (average ± SD).
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FIGURE 4. 
Aspartic protease is required for N-terminal product-mediated C-terminal product 
degradation. RAW macrophages expressing recombinant Myc-tagged C-terminal fragment 
transduced a retrovirus expressing TM-GFP or Nterm-TM-GFP, incubated for 6 h with 
DMSO, chloroquine (5 μM), or MG132 (10 μM) (A), or for 12 h with z-FA-fmk (10 μM) or 
pepstatin A (1 μM) (B); proteins were analyzed with anti-Myc, anti-GFP, or anti–β-actin by 
immunoblot. Data are representative of three independent experiments.
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FIGURE 5. 
The N-terminal cleavage product blocks TLR9 C-terminal fragment dimerization by 
physically interacting with the C-terminal fragment. (A) Immunoblot analyses of RAW 
macrophages expressing the Myc-tagged C-terminal fragment with or without the GFP-
tagged C-terminal fragment and incubated with CpG-DNA (1 μM) for 6 h at 37°C. Anti-
Myc was used for immunoprecipitation, and anti-GFP or anti-Myc were used for 
immunoblot analyses. (B) Analyses of immunoprecipitates of RAW macrophages stably 
expressing the Myc-tagged C-terminal fragment and GFP-tagged C-terminal fragment in the 
presence or absence of Nterm-TM-GFP. TLR9 C-terminal fragments recovered by 
immunoprecipitation with anti-Myc were treated with Endo F and immunoblotted with anti-
GFP. Arrowheads indicate C-terminal TLR9 fragments dimers. (C and D) Immunoblot 
analyses of RAW cells stably expressing TLR9 Cterm-Myc with TM-GFP or TLR9 Nterm-
TM-GFP, and incubated for 3 h at 37°C with biotinylated CpG-DNA (3 μM) in the absence 
(C) or presence of chloroquine (5 μM) (D); CpG-DNA and bond materials were precipitated 
with streptavidin-agarose and analyzed with anti-Myc or anti-GFP. (E) Flow cytometric 
Lee et al. Page 20
J Immunol. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
analyses of intracellular IL-6 in BMDCs from wild-type transduced with either TM-GFP or 
Nterm-TM-GFP, stimulated for 6 h with LPS (80 ng/ml) or CpG-DNA (1 μM) in the 
presence of brefeldin A (day 6 of culture). Cells were fixed and stained with the anti–IL-6 
Ab. (F) IL-6 production by immortalized TLR9−/− cells expressing Myc-tagged TLR9 with 
either TM-GFP or Nterm-TM-GFP induced by incubation with LPS (80 ng/ml) or CpG-
DNA (1 μM). (G) NF-κB luciferase reporter assays of HEK293T cells expressing the C-
terminal fragment of TLR9 in the presence of the indicated expression plasmids were 
performed 12 h after stimulation with 1 μM CpG-DNA. *p < 0.05, **p < 0.01 (Student t 
test). Data are representative of two (A–D) or three (E–G) independent experiments (average 
± SD).
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FIGURE 6. 
The N-terminal region of TLR9 has distinct functions based on cellular localization. (A) 
RAW macrophages stably expressing either wild-type TLR9-GFP or C-terminal TLR9 
fragments tagged with GFP (TLR9 Cterm-GFP) were stimulated with 1 μM CpG-DNA for 2 
h, washed, and imaged after an additional 3 h with LysoTracker. Quantitative analysis of 
lysosomal-targeted TLR9 (right graph). Values represent the average percentage of cells 
with lysosomal-targeted TLR9 (n = 40–60 cells). Scale bars, 5 μm. (B) RAW macrophages 
expressing either wild-type TLR9-GFP or recombinant Cterm-GFP were lysed with 1% 
digitonin lysis buffer. Unc93B1 proteins were immunoprecipitated using the anti-Unc93B1 
Ab. Immunoprecipitated samples were resolved by SDS-PAGE and analyzed using the anti-
GFP Ab. (C) Wild-type TLR9-Myc–expressing macrophages were labeled with 
[35S]methionine/cysteine for 1 h and chased for the indicated times. Metabolically labeled 
cells were lysed with 1% digitonin lysis buffer, and lysates were immunoprecipitated using 
the anti-Myc Ab. Data are representative of three independent experiments.
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